|
Market Closed -
Nasdaq
04:00:00 2026-10-06 pm EDT
|
After hours 08:00:00 pm | |||
| 187.46 USD | -7.75% |
|
190.13 | +1.42% |
| Oct. 05 | Global markets live: Goldman Sachs, Eli Lilly, Foxconn, Accenture, BT Group… |  |
| Oct. 05 | Wall Street Faces a Political Stress Test | |
| Market Cap | 74.84B 66.44B 62.17B 56.35B 106B 7,215B 107B 747B 290B 3,680B 281B 275B 11,832B | P/E 2026 * |
-22.4x | P/E 2027 * | -39.1x |
|---|---|---|---|---|---|
| Enterprise Value | 71.19B 63.19B 59.14B 53.6B 101B 6,862B 102B 710B 276B 3,501B 267B 261B 11,254B | EV / Sales 2026 * |
33.9x | EV / Sales 2027 * | 29.9x |
| Free-Float |
92.66% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| MRNA | Delayed | |
CBOE
| MRNA | Real-time | |
|
Tradegate
| 0QF | Real-time | |
|
Xetra
| 0QF | Delayed | |
|
Borsa Italiana
| 1MRNA | End-of-day quote | |
|
CBOE
| Real-time | ||
|
Boerse Muenchen
| 0QF | Real-time | |
|
CBOE
| 0A45 | Real-time | |
|
Mexican S.E.
| MRNA * | End-of-day quote | |
|
Börse Stuttgart
| 0QF | Delayed | |
|
Deutsche Boerse AG
| 0QF | Delayed | |
|
London S.E.
| 0A45 | Delayed | |
|
Wiener Boerse
| MRNA | End-of-day quote | |
|
Kazakhstan S.E.
| MRNA_KZ | End-of-day quote | |
|
Swiss Exchange
| MRNA | Delayed | |
|
Lima
| MRNAUS | End-of-day quote | |
|
Swiss Exchange
| MRNA | Delayed |
Last Transcript: Moderna, Inc.
| 1 day | +1.42% | ||
| 1 week | -7.86% | ||
| Current month | -2.65% | ||
| 1 month | +28.79% | ||
| 3 months | +129.17% | ||
| 6 months | +284.38% | ||
| Current year | +535.67% |
| 1 week | 183.28 |  | 212.22 |
| 1 month | 130.38 | | 212.22 |
| Current year | 29.81 | | 212.22 |
| 1 year | 22.28 | | 212.22 |
| 3 years | 22.28 | | 212.22 |
| 5 years | 22.28 | | 376.65 |
| 10 years | 11.54 | | 497.49 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 54 | 2011-02-28 |
James Mock
DFI | Director of Finance/CFO | 49 | 2022-09-05 |
Stephen Hoge
PSD | President | 50 | 2024-10-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Noubar Afeyan
CHM | Chairman | 63 | 2012-01-31 |
Stéphane Bancel
BRD | Director/Board Member | 54 | 2011-02-28 |
Francois Nader
BRD | Director/Board Member | 69 | 2019-12-10 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/15/26 | Exercice | Chairperson | 193,185 | 0.0484% | ||
| 9/10/26 | Exercice | Chief Financial Officer | 74,508 | 0.0187% | ||
| 9/4/26 | Exercice | General Counsel | 29,298 | 0.0073% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.75% | -7.86% | +580.68% | +80.46% | 74.84B | |
| +1.26% | -2.29% | +36.97% | +104.79% | 1,032B | |
| +0.73% | -4.78% | +35.41% | +61.62% | 614B | |
| +0.35% | +1.29% | +15.86% | +79.90% | 471B | |
| +1.72% | -4.92% | +59.84% | +36.64% | 350B | |
| +0.26% | +0.14% | +21.29% | +40.99% | 337B | |
| +0.60% | -3.09% | +10.76% | +32.59% | 268B | |
| +1.65% | -3.78% | -6.03% | +9.29% | 246B | |
| -0.09% | -4.97% | +36.88% | +50.52% | 218B | |
| -0.28% | -4.66% | +26.99% | +92.98% | 179B | |
| Average | +0.48% | -4.13% | +81.86% | +58.98% | 378.97B | |
| Weighted average by Cap. | +0.08% | -3.52% | +40.42% | +67.26% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.1B 1.87B 1.75B 1.58B 2.99B 203B 3.01B 20.96B 8.15B 103B 7.89B 7.72B 332B | 2.43B 2.16B 2.02B 1.83B 3.46B 235B 3.49B 24.28B 9.45B 120B 9.14B 8.94B 385B |
| Net income | -3.31B -2.94B -2.75B -2.49B -4.71B -319B -4.74B -33.04B -12.85B -163B -12.43B -12.16B -523B | -1.95B -1.73B -1.62B -1.47B -2.77B -188B -2.79B -19.42B -7.55B -95.73B -7.31B -7.15B -308B |
| Net Debt | -3.65B -3.24B -3.03B -2.75B -5.19B -352B -5.23B -36.45B -14.18B -180B -13.71B -13.42B -577B | -2.17B -1.93B -1.8B -1.63B -3.09B -209B -3.11B -21.65B -8.42B -107B -8.15B -7.97B -343B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-06 | $187.46 | -7.75% | 18,794,807 |
| 26-10-05 | $203.21 | +6.95% | 19,313,307 |
| 26-10-02 | $190.01 | +0.57% | 10,289,461 |
| 26-10-01 | $188.94 | -1.89% | 15,437,001 |
| 26-09-30 | $192.57 | -5.35% | 20,649,483 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MRNA Stock
Select your edition
All financial news and data tailored to specific country editions
